Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 838

recruiting
3 968
countries
28
conditions
2 103

10 282 trials match your criteria

Plasma cell myeloma refractory

Not recruiting

Study of isatuximab and pegenzileukin combination treatment for patients with relapsed or refractory multiple myeloma who previously received anti-CD38 and anti-BCMA therapy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Isatuximab

Cardiac arrest

Not recruiting

Study on the Effects of Dexamethasone and Olanzapine in Patients Resuscitated from Out-of-Hospital Cardiac Arrest

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Olanzapine

Myocardial infarction

Not recruiting

Study on Prasugrel or Ticagrelor for Patients with Atrial Fibrillation and Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid

Breast cancer+1

Not recruiting

Study on Cyclophosphamide for Patients with Advanced Breast Cancer with TP53 Mutations

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Pancreatic neuroendocrine tumour

Not recruiting

Study of Ramucirumab and Dacarbazine for Patients with Progressive Metastatic Pancreatic Neuroendocrine Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ramucirumab

Plasma cell myeloma

Not recruiting

Study Comparing Selinexor, Pomalidomide, and Dexamethasone with Elotuzumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone

Gastrooesophageal cancer+1

Not recruiting

Study of Pembrolizumab, Trastuzumab, and Drug Combination for Patients with HER2-Positive, Localized Esophagogastric Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Disodium Folinate

Plasma cell myeloma refractory

Not recruiting

Study of isatuximab, belantamab mafodotin and dexamethasone combination for patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Belantamab Mafodotin

Plasma cell myeloma

Not recruiting

Study of Isatuximab with Lenalidomide and Dexamethasone for Elderly Patients (70+) with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:65+ years
  • Substances:Isatuximab

Dementia Alzheimer's type

Not recruiting

Study on Lecanemab for Patients with Dominantly Inherited Alzheimer's Disease to Evaluate Prevention and Progression

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lecanemab

Neurodermatitis

Not recruiting

Study of Rocatinlimab in Adults with Prurigo Nodularis Not Adequately Controlled by Topical Treatments

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab

Myasthenia gravis

Not recruiting

Study on Cladribine for Treating Seropositive Myasthenia Gravis in Patients

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cladribine

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.